TRAIL Induces Nuclear Translocation and Chromatin Localization of TRAIL Death Receptors.

CRM-1 TRAIL nuclear TRAIL-R1 nuclear TRAIL-R2 trafficking

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
14 Aug 2019
Historique:
received: 02 08 2019
accepted: 08 08 2019
entrez: 17 8 2019
pubmed: 17 8 2019
medline: 17 8 2019
Statut: epublish

Résumé

Binding of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to the plasma membrane TRAIL-R1/-R2 selectively kills tumor cells. This discovery led to evaluation of TRAIL-R1/-R2 as targets for anti-cancer therapy, yet the corresponding clinical trials were disappointing. Meanwhile, it emerged that many cancer cells are TRAIL-resistant and that TRAIL-R1/-R2-triggering may lead to tumor-promoting effects. Intriguingly, recent studies uncovered specific functions of long ignored intracellular TRAIL-R1/-R2, with tumor-promoting functions of nuclear (n)TRAIL-R2 as the regulator of let-7-maturation. As nuclear trafficking of TRAIL-Rs is not well understood, we addressed this issue in our present study. Cell surface biotinylation and tracking of biotinylated proteins in intracellular compartments revealed that nTRAIL-Rs originate from the plasma membrane. Nuclear TRAIL-Rs-trafficking is a fast process, requiring clathrin-dependent endocytosis and it is TRAIL-dependent. Immunoprecipitation and immunofluorescence approaches revealed an interaction of nTRAIL-R2 with the nucleo-cytoplasmic shuttle protein Exportin-1/CRM-1. Mutation of a putative nuclear export sequence (NES) in TRAIL-R2 or the inhibition of CRM-1 by Leptomycin-B resulted in the nuclear accumulation of TRAIL-R2. In addition, TRAIL-R1 and TRAIL-R2 constitutively localize to chromatin, which is strongly enhanced by TRAIL-treatment. Our data highlight the novel role for surface-activated TRAIL-Rs by direct trafficking and signaling into the nucleus, a previously unknown signaling principle for cell surface receptors that belong to the TNF-superfamily.

Identifiants

pubmed: 31416165
pii: cancers11081167
doi: 10.3390/cancers11081167
pmc: PMC6721811
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : TR1063/6-1

Références

J Clin Invest. 1999 Jul;104(2):155-62
pubmed: 10411544
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9112-7
pubmed: 10430904
Immunity. 2000 Jun;12(6):599-609
pubmed: 10894160
Immunity. 2000 Jun;12(6):611-20
pubmed: 10894161
Exp Cell Res. 2000 Jul 10;258(1):121-34
pubmed: 10912794
J Biol Chem. 2001 May 4;276(18):14939-45
pubmed: 11279061
Oncogene. 2001 Jul 12;20(31):4258-69
pubmed: 11464292
J Immunol. 2001 Dec 15;167(12):6736-44
pubmed: 11739488
J Biol Chem. 2002 Sep 13;277(37):34217-22
pubmed: 12065591
Cell Death Differ. 2003 Jul;10(7):791-7
pubmed: 12815462
Blood. 2004 Jan 15;103(2):517-22
pubmed: 12969966
Cancer Res. 2003 Nov 1;63(21):7284-90
pubmed: 14612525
Cancer Res. 2004 Feb 1;64(3):1037-43
pubmed: 14871835
Protein Eng Des Sel. 2004 Jun;17(6):527-36
pubmed: 15314210
EMBO J. 2004 Sep 15;23(18):3643-52
pubmed: 15329671
J Cell Physiol. 2005 Mar;202(3):900-11
pubmed: 15389633
Blood. 2005 Feb 1;105(3):1003-9
pubmed: 15454491
Trends Cell Biol. 2005 Mar;15(3):121-4
pubmed: 15752974
Cancer Cell. 2005 Jun;7(6):575-89
pubmed: 15950906
J Biol Chem. 2005 Sep 2;280(35):31182-9
pubmed: 16000298
Traffic. 2005 Oct;6(10):947-54
pubmed: 16138907
Am J Physiol Gastrointest Liver Physiol. 2006 Jan;290(1):G129-36
pubmed: 16166346
J Biol Chem. 2005 Dec 23;280(51):41940-52
pubmed: 16234248
Mol Carcinog. 2006 Jan;45(1):10-7
pubmed: 16299810
Mol Cell Biol. 2005 Dec;25(24):11005-18
pubmed: 16314522
Oncogene. 2006 Nov 30;25(56):7434-9
pubmed: 16751802
Cell. 2006 Aug 11;126(3):503-14
pubmed: 16901784
Mol Cell Biol. 2006 Oct;26(19):7046-55
pubmed: 16980609
Nat Cell Biol. 2006 Dec;8(12):1359-68
pubmed: 17115032
Mol Biol Cell. 2007 Mar;18(3):1064-72
pubmed: 17215517
Cell Signal. 2007 Jun;19(6):1172-84
pubmed: 17291719
J Biol Chem. 2007 Apr 27;282(17):12831-41
pubmed: 17327223
Annu Rev Biochem. 2007;76:647-71
pubmed: 17506639
Blood. 2007 Sep 15;110(6):2121-7
pubmed: 17567982
Adv Exp Med Biol. 2008;615:127-58
pubmed: 18437894
Nucleic Acids Res. 2008 Aug;36(13):4337-51
pubmed: 18586824
Curr Med Chem. 2008;15(26):2648-55
pubmed: 18991627
Mol Cancer Res. 2008 Dec;6(12):1861-71
pubmed: 19074831
Blood. 2009 May 7;113(19):4627-36
pubmed: 19258594
Cancer Biol Ther. 2009 May;8(10):917-22
pubmed: 19270498
Gastroenterology. 2009 Jun;136(7):2365-2376.e1-7
pubmed: 19272388
Am J Transl Res. 2009 Mar 08;1(3):249-58
pubmed: 19956435
Mol Cancer Res. 2010 Feb;8(2):232-45
pubmed: 20145033
Gastroenterology. 2010 Jun;138(7):2357-67
pubmed: 20188103
J Mol Med (Berl). 2010 Jul;88(7):729-40
pubmed: 20354842
Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16125-30
pubmed: 20802156
Cancer Res. 2011 Feb 1;71(3):1103-14
pubmed: 21266349
J Biol Chem. 2011 Dec 16;286(50):43383-93
pubmed: 22020938
Discov Med. 2011 Nov;12(66):419-32
pubmed: 22127113
Mol Cell Biol. 2012 Jun;32(12):2183-95
pubmed: 22473997
Cell Biosci. 2012 Apr 20;2(1):13
pubmed: 22520625
Int J Biochem Mol Biol. 2012;3(2):137-51
pubmed: 22773955
J Cell Sci. 2012 Oct 1;125(Pt 19):4651-61
pubmed: 22797920
Oncotarget. 2012 Aug;3(8):833-42
pubmed: 22909995
Cell Death Differ. 2013 Jul;20(7):858-68
pubmed: 23579241
Oncotarget. 2013 Sep;4(9):1349-64
pubmed: 23988408
Gastroenterology. 2014 Jan;146(1):278-90
pubmed: 24120475
BMC Cancer. 2013 Nov 09;13:532
pubmed: 24209510
BMC Cancer. 2014 Feb 07;14:74
pubmed: 24507727
J Biol Chem. 2014 Jun 6;289(23):16576-87
pubmed: 24764293
Science. 2014 Jul 4;345(6192):98-101
pubmed: 24994655
Cell Death Dis. 2014 Aug 28;5:e1390
pubmed: 25165876
Cancer Cell. 2015 Apr 13;27(4):561-73
pubmed: 25843002
Cell Death Differ. 2016 Feb;23(2):253-60
pubmed: 26184911
Cell Death Differ. 2016 May;23(5):733-47
pubmed: 26943322
Oncotarget. 2017 Feb 7;8(6):9974-9985
pubmed: 28039489
Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):504-509
pubmed: 28049841
Mol Cell. 2017 Feb 16;65(4):715-729.e5
pubmed: 28212752
Mol Cell. 2017 Feb 16;65(4):730-742.e5
pubmed: 28212753
Nat Rev Cancer. 2017 May 24;17(6):352-366
pubmed: 28536452
Cancer Cell. 2017 Sep 11;32(3):342-359.e10
pubmed: 28898696
BMC Cancer. 2018 Jul 31;18(1):777
pubmed: 30064384
Science. 1997 Apr 4;276(5309):111-3
pubmed: 9082980
Science. 1997 Aug 8;277(5327):815-8
pubmed: 9242610
Curr Biol. 1997 Sep 1;7(9):693-6
pubmed: 9285725
EMBO J. 1997 Sep 1;16(17):5386-97
pubmed: 9311998
J Exp Med. 1997 Oct 6;186(7):1165-70
pubmed: 9314565
Immunity. 1997 Dec;7(6):813-20
pubmed: 9430226
Nat Med. 1999 Feb;5(2):157-63
pubmed: 9930862

Auteurs

Ufuk Mert (U)

Institute for Experimental Cancer Research, University of Kiel, 24105 Kiel, Germany.

Alshaimaa Adawy (A)

Institute for Experimental Cancer Research, University of Kiel, 24105 Kiel, Germany.

Elisabeth Scharff (E)

Institute for Experimental Cancer Research, University of Kiel, 24105 Kiel, Germany.

Pierre Teichmann (P)

Institute for Experimental Cancer Research, University of Kiel, 24105 Kiel, Germany.

Anna Willms (A)

Institute for Experimental Cancer Research, University of Kiel, 24105 Kiel, Germany.

Verena Haselmann (V)

Department of Clinical Chemistry, University Medical Centre, Ruprecht-Karls University of Heidelberg, 68167 Mannheim, Germany.

Cynthia Colmorgen (C)

Institute for Experimental Cancer Research, University of Kiel, 24105 Kiel, Germany.

Johannes Lemke (J)

Department of General and Visceral Surgery, Ulm University Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany.

Silvia von Karstedt (S)

Department of Translational Genomics, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
CECAD Research Center, Medical Faculty, University of Cologne, 50931 Cologne, Germany.

Jürgen Fritsch (J)

Department of Infection Prevention and Infectious Diseases, University of Regensburg, 93053 Regensburg, Germany.

Anna Trauzold (A)

Institute for Experimental Cancer Research, University of Kiel, 24105 Kiel, Germany. atrauzold@email.uni-kiel.de.

Classifications MeSH